Trials / Completed
CompletedNCT01908465
Peripheral Histamine 1 Receptor Blockade in IBS: Multicenter Trial
Peripheral Histamine 1 Receptor Blockade in IBS
- Status
- Completed
- Phase
- Phase 4
- Study type
- Interventional
- Enrollment
- 200 (actual)
- Sponsor
- KU Leuven · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Purpose: To evaluate the efficiency of Irritable Bowel Syndrome (IBS) patients treatment with the H1-receptor antagonist ebastine. Design: Double blind randomized placebo controlled trial. IBS patients receive a 12-weeks treatment with ebastine 20mg once daily or placebo (1:1 randomization).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ebastine | |
| DRUG | Placebo |
Timeline
- Start date
- 2013-11-01
- Primary completion
- 2022-11-02
- Completion
- 2022-11-02
- First posted
- 2013-07-25
- Last updated
- 2023-02-08
Locations
12 sites across 2 countries: Belgium, Netherlands
Source: ClinicalTrials.gov record NCT01908465. Inclusion in this directory is not an endorsement.